The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Not through the temporary shortage-based pathway that allowed copies of injectable semaglutide and tirzepatide. FDA determined those shortages were resolved and the transition periods for compounders ended in 2025. But that is not a blanket ban on all compounding: federal law still permits limited compounding under other conditions. In August 2026, an appeals court upheld FDA’s decision on tirzepatide; a separate FDA proposal concerning certain ingredients had not been shown finalized in the agency announcement cited here.
Can pharmacies still compound semaglutide or tirzepatide?
The key change is that pharmacies and outsourcing facilities can no longer rely on the shortage-based exception to make essentially copies of these drugs after FDA’s shortage determinations and the related transition periods. That exception applied while the relevant approved drug was listed in shortage; it was not a permanent permission to sell a cheaper or alternative version.
Other compounding pathways remain, but they are limited and fact-specific. Compounding is not the same as manufacturing an FDA-approved generic, and a compounded product is not FDA-approved.
| Pathway | What the rule permits | What it does not establish |
|---|---|---|
| 503A pharmacy | Compounding for an individual patient based on a prescription, subject to applicable conditions. | A general authorization to routinely make copies of commercially available drugs. FDA’s 2026 guidance says 503A pharmacies must not regularly or in inordinate amounts compound essentially copies, subject to narrow exceptions. |
| 503B outsourcing facility | Compounding under the statutory conditions for outsourcing facilities. | A blanket right to make a drug from bulk substances whenever patients or prescribers prefer a compounded version. FDA’s 2026 proposal addresses whether certain ingredients may be used by 503B facilities. |
For an individual prescription, the relevant question is not simply whether a patient wants a different version. The pharmacy must meet the requirements that apply to its type of facility and the specific circumstances, including any required patient-specific clinical difference. The FDA material summarized here does not establish that a particular prescription qualifies.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Clear out junk files and repair common Windows errorsFree Scan →#1 Best Overall
- 12 MONTH WEIGHT LOSS TRACKER Track your weight loss journey over 12 months with a guided journal designed for recording pounds lost, body measurements, goals and progress.
- POUNDS LOST & BODY MEASUREMENTS Includes 10, 20, 30, 50 and 100 pounds lost trackers, plus body measurement tracking to help you visually follow your progress over time.
- MONTHLY STEP & FITNESS TRACKERS Plan and record movement with monthly step trackers and monthly fitness planner pages, ideal for building consistency around activity and fitness goals.
- VITAMINS, SUPPLEMENTS & REFLECTIONS Includes vitamins and supplements trackers, plus goals and reflections sections to help you stay organised and review your progress throughout the year.
- CHALLENGES TO KEEP YOU MOTIVATED Features 30 day, 12 week and 52 week challenges, giving you different ways to stay focused and create momentum across your weight loss journey.
Why did FDA say the shortages were over?
FDA’s dates were specific to the injectable products. The agency first announced that tirzepatide injection was no longer in shortage on October 2, 2024, but that decision was remanded to FDA for reevaluation after litigation. On December 19, 2024, FDA again determined the tirzepatide injection shortage was resolved. It determined the semaglutide injection shortage was resolved on February 21, 2025.
FDA allowed temporary transition periods for compounders. The agency described enforcement discretion for 503B facilities making tirzepatide through March 19, 2025. For semaglutide, it described transition periods through April 22, 2025 for 503A compounders and May 22, 2025 for 503B facilities, subject to qualifications in FDA’s litigation-related updates. Those periods have passed.
Rank #2
- FOOD JOURNAL FOR HEALTHY - A food journal to tracks daily dietary and nutritional intake for women/men. It will help you stay healthy, get motivated, get rid of bad habits, and achieve your weight loss goals. Focus on your health and eat healthy, this food tracker is all about what you want to improve.
- ACHIEVE GOALS - This fitness and nutrition journal helps you set big goals, break them down into monthly milestones, and work relentlessly toward them. At the end of each month, you will complete a monthly review to reflect your progress.
- UNDATED 6 MONTH MEAL PLANNER - This is a food diary that tracks meals and exercise last for 6 month. Keep daily records of calories, sleep time, water, weight, body fat, and activity. The monthly record can help you pay attention to your health and notice how changing your diet and lifestyle affects how you feel.
- ADDITIONAL - Lovely patterns created by hardcover, high quality of size 5.8" x 8.3", There are 3 sheets colorful stickers to help you plan and stay motivated to continue using this daily journal. What's more, the food journal with 3 ribbon bookmark, elastic band, pen holder and inner pocket for easy use.
- GUARANTEE - If you have any problems with this food journal, please contact us and we will help you solve promptly!
The determinations concern the injectable drugs and the shortage-based compounding pathway. They should not be stretched into a claim about every presentation, every local pharmacy’s inventory, or every possible legal basis for compounding.
Are compounded versions the same as Ozempic, Wegovy, Mounjaro, or Zepbound?
No. The brand names refer to FDA-approved medicines: Ozempic and Wegovy contain semaglutide, while Mounjaro and Zepbound contain tirzepatide. Compounded versions are prepared by a pharmacy or outsourcing facility and do not undergo the same FDA premarket review for safety, effectiveness, and quality as approved medicines. They should not be described as FDA-approved generics or assumed to be interchangeable with the branded products.
Formulation and dose handling matter. FDA has reported dosing errors involving compounded injectable semaglutide, including patients measuring or administering the wrong amount and clinician dose-calculation errors. Some reports involved doses beyond those in the approved label. FDA has also warned that semaglutide sodium and semaglutide acetate are salt forms different from the active ingredient in approved drugs; the agency says it does not know whether those salts have the same chemical and pharmacologic properties and is unaware of a lawful basis for their use in compounding.
What did the court decide about compounded tirzepatide?
On August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit affirmed the district court’s ruling in Outsourcing Facilities Association v. FDA. Compounders and their trade association had challenged FDA’s determination that the tirzepatide injection shortage was resolved. The panel rejected the Administrative Procedure Act arguments presented and concluded the agency’s decision was not arbitrary or capricious. The opinion said, “The FDA did not act arbitrarily in concluding that Eli Lilly’s supply would meet or exceed projected demand.”
Rank #4
- 150-day/5-month food and fitness journal with measuring tape: this fitness journal allows you to record up to 150 days of fitness and diet data, ensuring you stay on track with your health goals. The measuring tape helps you to track your body dimensions and detailed tracking system helps you monitor progress and make necessary adjustments to your routine
- Structured goal setting and achievement: the 2 goal pages of fitness planner has 10 sections for setting clear objectives, start and end dates, detailed plans, and results. The workout journal also features a reward section to motivate you to achieve your fitness milestones
- Body dimension contrasts by table, photos and chart: the body dimension contrasts can be shown by figures, photos, and progress curves. This visual representation allows you to see tangible changes in your physique over time, providing motivation and a clear sense of achievement
- Integrated calendar and daily tracking: the 2-page undated calendar of weight loss journal provides a monthly overview with daily completion marks and progress curves. The daily tracking pages allow you to log specific exercises, calories burned, and meal calorie intake. This integrated system helps you maintain a consistent routine and stay accountable to your fitness and nutrition goals
- User-friendly design, durable material: the 9.5'' * 7'' fitness journal for women is easy to carry and use, with a waterproof and sweat-proof PP material cover and ink-resistant 100gsm thick paper inside. The elastic band keeps the workout planner closed to keep your data private and organized. Double sided pockets are designed for cards, guidebooks, etc.
That ruling concerns FDA’s tirzepatide shortage determination. It does not decide every dispute over compounded GLP-1 drugs, nor does it establish that every patient will find an approved product in stock at a particular pharmacy.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Is FDA banning all compounded weight-loss drugs?
No. The shortage-based route for making essentially copies of injectable semaglutide and tirzepatide ended after FDA’s determinations and transition periods, but the agency’s broader compounding framework remains. Whether a specific compounded prescription is lawful depends on the applicable statutory pathway and circumstances.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Best Value
- SMASH YOUR PB'S - Achieve the performance and physique you've always wanted with Nextnoid daily workout journal! Effectively track both daily and weekly workout goals upto 8 months as meticulously as you desire, plan next week's workouts, and celebrate your success with ease. Stay focused!
- GET FITTER, FASTER - Take control of your health and fitness journey and accelerate your results with our fitness planner for women and men! This exercise diary provides you with a proven system to build muscle, improve strength or just be healthier. What gets measured, improves!
- SIMPLE AND CLEAR - Setting yourself up for success has never been easier! Our personal workout book takes the thought and effort out of staying disciplined and accountable with a clear incremental progress system, bigger fonts for easy reading and enough space to jot down everything.
- CAREFULLY CRAFTED - Made with functionality and also long-lasting durability in mind with size 5.7x8.3 in, this fit log journal is tough enough to withstand the rigors of the gym floor, running trail and even the kitchen! Premium thick 120gsm pages and a sweat and tear-proof outer match your grit!
- PERFECT GIFT - Show the fitness enthusiast in your life just how much you care with this workout tracker notebook! Also ideal for the beginner who dreams of being in shape, this fitness training journal could be the motivation they need to kickstart their health and wellness journey!
Separately, in April 2026 FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, saying it found no clinical need for outsourcing facilities to compound them from bulk substances. FDA Commissioner Marty Makary said at the time, “When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need,”. The agency’s announcement set a June 29, 2026 comment deadline; it described a proposal, not a final decision. The cited announcement does not establish what action, if any, FDA took after comments closed, so it should not be treated by itself as proof that the proposal became a final rule.
What safety information has FDA reported?
As of May 31, 2026, FDA reported 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. FDA cautions that reports do not prove the drug caused an event; other factors may be involved. The totals are reports, not rates of harm, and they cannot be used to calculate how likely a patient is to experience an adverse event. Reports may also be incomplete: federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse-event reports.
FDA separately warns about fraudulent products and dosing problems. A compounded product is not automatically counterfeit, but consumers should not assume that a product sold online or promoted as a compounded version is legitimate or properly handled. FDA’s concerns include reports of dosing errors, quality questions, and products that may not contain the expected ingredient.
What does this mean for a patient’s budget?
The regulatory change does not establish what any patient will pay. The sources cited here do not provide current, comparable prices, insurance coverage, or manufacturer-program eligibility for approved and compounded products. A lower advertised price alone does not show that a compounded product is legally available for a particular prescription or equivalent to an approved medicine. Patients weighing options can ask their prescriber and pharmacist what product is being prescribed, whether it is FDA-approved, how the dose is measured, and what their own pharmacy and insurer will charge.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
